Graphene Manufacturing Group Ltd (TSX-V:GMG, OTC:GMGMF) has announced new moves to support the research and development of its graphene technology and production, which it says will “support and accelerate” the company's next phase of development.
The previously separate Technology and Projects teams will be combined into the Projects Team to better integrate the R&D of graphene production with the development of the graphene production plant, the liquid graphene blend plant and the targeted development of the automated battery manufacturing pilot plant, the company said in a statement.
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) has announced that it is planning a 180-patient, 90-day, Phase 2b clinical study of NP-120 (Ifenprodil) for chronic cough set to begin in the third quarter of this year.
The company said in a statement that Ifenprodil represented a novel first-in-class potential treatment for chronic cough and is thought to interfere with central signalling in the brain, suppressing the urge to cough.
AMPD Ventures Inc (CSE:AMPD, OTCQB:AMPDF) said that Tanya Woods resigned from its board of directors and the AMPD audit committee, effective December 23, 2022. Woods's resignation follows from her decision to take on a new full-time role with increased professional commitments that will limit her availability to actively serve as a director on the AMPD board of directors and its audit committee. "It has been a privilege to support AMPD's board and ambitious corporate vision," commented Woods. "I wish the team all the best as they continue building out next-generation technology and computing infrastructure." AMPD Ventures said its board of directors are currently evaluating alternatives with respect to appointing a new independent director to fill the vacancy. "We are sorry that Tanya is leaving the board and we are very pleased with her input and performance to date," said Anthony Brown, chief executive officer of AMPD Ventures. "We wish her all the best in her new position and look forward to working with her again in the future in whatever capacity possible."
G Mining Ventures Corp (TSX-V:GMIN, OTCQX:GMINF) said it has filed a preliminary short-form base shelf prospectus with the securities regulators in each province and territory of Canada. When made final or effective, this filing will allow the corporation and/or selling security holders to make offerings of common shares (including by way of an "at-the-market distribution" in accordance with applicable securities laws), preferred shares, subscription receipts, warrants, debt securities, units or any combination thereof for up to a maximum amount of C$500 million during the 25-month period over which the base shelf prospectus is effective. The corporation has filed this preliminary base shelf prospectus in order to have greater financial flexibility going forward but has no immediate plans to issue any securities under it at this time, and may never proceed with any such issuance.
Maverix Metals Inc (TSX:MMX) has announced that as a result of minor delays in materials being received during the holiday season and at the request of the Depository Trust and Clearing Corporation (DTCC) the deadline for shareholders to elect to receive either "all cash" or "all shares" as their form of consideration under the plan of agreement involving Maverix and Triple Flag Precious Metals Corp has been extended to 5.00pm Toronto time)on January 11, 2023. A special meeting of the holders of common shares of Maverix will be held on January 12, 2023, at 10.00am Pacific time and the cut-off time for shareholders to vote their shares or deliver their proxies with regards to the arrangement is 10.00am Pacific time on January 10, 2023.
Phunware Inc (NASDAQ:PHUN) said it has made an inducement grant to Russell Buyse in connection with his employment as the company's new chief executive officer, effective December 28, 2022. Phunware’s board of directors granted Buyse an aggregate of 1,470,588 restricted stock units under its inducement plan. The grant was included in Buyse’s employment agreement. The restricted stock units granted are subject to a vesting schedule commencing on December 28, 2022, with one-third of the restricted stock units vesting on each anniversary of the commencement date, subject to Buyse’s continued employment.
Psyched Wellness Ltd (CSE:PSYC, OTCQB:PSYCF) announced that effective January 5, 2023, it has cancelled an aggregate 7,150,000 options to purchase common shares of the company, which were previously granted to board members, advisory board members, employees, advisors and consultants of the company. It said its management reviewed the outstanding options and determined that certain options granted at exercise prices ranging from $0.145 to $0.39 per common share, no longer represented a realistic incentive to motivate such Participants. As such, the company, in compliance with the policies of the Canadian Securities Exchange (CSE), intends to grant an equal number of options to such participants 30 days after the effective date at an exercise price equal to the greater of: (i) $0.10; and (ii) the closing price of the common shares on the CSE on February 3, 2023. Such options will vest immediately, expire three years from the date of grant and are being granted so that all outstanding options are at a similar level to each other and provide a realistic incentive to motivate such participants.
enCore Energy Corp. (TSX-V:EU, OTCQB:ENCUF) has announced that the previously announced purchase of the Alta Mesa project from Energy Fuels Inc is scheduled to close on or before February 15, 2023. Closing is subject to obtaining final stock exchange approval and all closing conditions.
Toubani Resources Inc. (TSX-V:TRE, ASX:TRE) has granted new CEO Phil Russo a total of 2 million stock options pursuant to the company`s stock option plan. One million stock options have an exercise price of A$0.35 and vest after 12 months from the date of grant and 1 million stock options have an exercise price of A$0.50 and vest after 24 months from the date of grant. All the options expire on January 9th, 2026.
Outlook Therapeutics Inc (NASDAQ:OTLK) announced that CEO Russ Trenary will present at the Virtual Investor 2023 Companies to Watch Event on Tuesday, January 17, 2023 at 11:00 AM ET. A live video webcast of the presentation will be available on the Events page of the Investors section of Outlook Therapeutics’ website (outlooktherapeutics.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
MySize Inc (NASDAQ:MYSZ) announced it will exhibit its suite of products including FirstLook Smart Mirror and its digital sizing solutions, MySizeID and Naiz Fit, at the National Retail Federation's "NRF 2023 Retail's Big Show" which takes place January 14 through 17 at the Jacob K. Javitz Convention Center in New York City. CEO Ronen Luzon, Chief Commercial Officer, Javier Brandwain, and Co-Founder of Naiz Fit, Borja Cembrero Saralegui, will be exhibiting at booth #4257 co-hosted by GK Software. "This year's NRF show will focus on topics including how innovation can solve issues of sustainability and increase business efficiency. MySize's suite of AI-driven sizing solutions is gaining considerable traction among apparel retailers worldwide for exactly these same reasons—we are improving brands' environmental sustainability while also reducing the cost of size-related returns," stated CEO Ronen Luzon.
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) said that a new independent study from the University of Toronto found that its oral drug Bucillamine had the most potent effect on COVID-19 Omicron variants when tested alongside other FDA-approved mild anti-oxidants. The study evaluated the potential disruption of the SARS-CoV-2 virus spike protein, which is done to prevent viral entry into the host cells. The company has a Type C meeting with the US Food & Drug Administration to potentially obtain agreement on revised protocol endpoints for the company’s Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine.